Skip to content

Evaluation of Safety, Tolerance and Effects on the Intestinal Flora of a New Fermented Milk for Preterm Infants

Evaluation of a Fermented Formula Without Live Bacteria for Preterm Infants: Effects on Microbiota Species and Intestinal Inflammatory Markers

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00711633
Enrollment
58
Registered
2008-07-09
Start date
2002-12-31
Completion date
2007-06-30
Last updated
2008-07-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Preterms With Gestational Age Ranging From 30 to 35 Weeks

Keywords

Premature birth,, infant,, infant formula,, bacterial colonization,, Bifidobacterium,, calprotectin

Brief summary

The intestinal flora is a complex ecosystem which is known to play various important functions in the gut. Recent data have reported a delay in intestinal colonization in preterm. Modulating the intestinal flora through dietary supplementation with probiotics or prebiotics has been shown to improve digestive and general outcomes in full-term infants.The aim of this study was to evaluate the clinical tolerance, the effect on gut microbiota, and the mucosal inflammatory responses to a fermented milk in preterm infants.

Detailed description

This prospective, randomized, double-blind, controlled study evaluated the safety and effect on gut microbiota, and the mucosal inflammatory responses to a fermented milk in preterm infants. Preterm infants with a gestational age (GA) ranging from 30 to 35 weeks and whose mother chose formula feeding were enrolled during their first three days of life. Both parents provided informed written consent. Infants were randomly assigned to receive either the fermented preterm formula (FPF) or, as a control, a formula adapted for preterm infants (PF). The PF was formulated to meet the nutritional needs of preterm infants. The FPF was identical, except for a manufacturing process including a fermentation step with two probiotic strains, Bifidobacterium breve C50 and Streptococcus thermophilus 065, inactivated by heat at the end of the manufacturing process. This process conferred a probiotic/prebiotic activity.For each neonate, background information about the pregnancy and neonatal parameters were collected. Anthropometric parameters (weight, height, head circumference); gastrointestinal tolerance parameters (abdominal distension, gastric residuals, rectal bleeding, NEC); drug administration; and intake of formula and mother's milk were recorded twice a week until discharge. Stools were collected twice a week from diapers for microbiological analysis and measurement of fecal inflammatory markers. All samples were immediately stored at -80°C.

Interventions

DIETARY_SUPPLEMENTMilk with probiotic and prebiotic activities

Comparison of two different formula for preterm infants

DIETARY_SUPPLEMENTMilk without probiotic and prebiotic activities

Comparison of formula for preterm infants

Sponsors

Blédina SA, Villefranche sur Saône, France
CollaboratorUNKNOWN
Assistance Publique - Hôpitaux de Paris
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
DOUBLE (Subject, Investigator)

Eligibility

Sex/Gender
ALL
Age
1 Days to 15 Days
Healthy volunteers
No

Inclusion criteria

* Preterms with gestational age ranging from 30 to 35 weeks * Eutrophic * Formula feeding

Exclusion criteria

* Malformation or metabolic disease * Newborns whose parents did not provide informed consent * Contraindication to enteral feeding

Design outcomes

Primary

MeasureTime frame
Follow-up of the number of colonized infants and the bacterial colonization levelsweekly until hospital discharge

Secondary

MeasureTime frame
Clinical toleranceweekly until hospital discharge
Levels of intestinal immune and inflammatory markersweekly until hospital discharge

Countries

France

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026